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ABSTRAK 
KAJIAN MENGENAI PREDIKTOR KLINIKAL 
SERANGANPENDARAHANDANISKEN.UASTROK 
DI JABATAN KECEMASAN HKL: 
KAJIAN PEMERHATIAN 
PENGENALAN: 
Kemunculan rawatan reperfusi untuk serangan akut strok iskemia telah mengubah 
cara rawatan serangan akut strok iskemia. Walaubagaimanapun, cara rawatan ini telah 
kurang berjaya disebabkan kurangnya keperhatinan di kalangan pesakit, masyarakat and 
kakitangan perubatan. Ini mungkin disebabkan kekurangan pengetahuan di kalangan 
mereka yang terlibat. 
Tujuan kajian ini dibuat adalah untuk melihat tanda-tanda dan aduan-aduan biasa 
dalam serangan strok dan membezakan secara selamat diantara kedua-dua jenis strok. 
Kajian ini juga bertujuan untuk melihat masa yang diambil oleh pesakit untuk sampai di 
hospital. 
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KAEDAB: 
Kajian pemerhatian hirisan lintang telah dilakukan kepada semua pesakit yang 
telah disahkan secara klinikal mendapat serangan akut strok yang telah dimasukkan ke 
HKL mulai dari Januari sehingga Mei 2005 setelah memenuhi kriteria kemasukkan dan 
kekeluaran. Semua pesakit mendapat pemeriksaan CT otak. 
Tanda-tanda dan aduan-aduan biasa yang dikaji adalah: Umur, jantina, kaum, 
Glasgow Coma Scale, tekanan darah sistolik dan diastolik, pitam, sakit kepala dan 
muntah. 
KEPUTUSAN: 
Seramai seratus empat puluh tiga (Lapan puluh Iapan lelaki dan lima puluh lima 
perempuan) pesakit telah dimasukkan untuk kajian. Enam puluh empat perpuluhan tiga 
peratus pesakit telah datang ke hospital selepas enam jam tanda-tanda awal strok bennula 
dengan majoritinya adalah pesakit strok iskemia. Pesakit strok pendarahan mempunyai 
kemungkinan lebih muda (mean umur lima puluh satu tahun berbanding lima puluh enam 
tahun)t dan mempunyai tanda-tanda seperti pi tam ( dua puluh tiga perpuluhan satu 
peratus: nilai p lebih rendah dari 0.001), sakit kepala (Iapan belas perpuluhan dua peratus: 
xiv 
nilai p lebih rendah dari 0.001), muntah (sembilan perpuluhan Iapan peratus: nilai p lebih 
rendah dari 0.001), Glasgow Coma Scale yang lebih rendah (mean=9, Standard 
Deviation=2.8) dan tekanan darah sistolik yang lebih tinggi (mean 174.77, Standard 
Deviation=22.5). 
RUMUSAN: 
Prediktor yang berkesan untuk pesakit strok berkemungkinan mendapat jenis 
pendarahan adalah umur yang lebih muda dan mempunyai tanda-tanda seperti pitam, 
sakit kepala dan muntah, dan Glasgow Coma Scale yang lebih rendah dan tekanan darah 
sistolik yang lebih tinggi. Pesakit strok jenis iskemia mempunyai kemungkinan untuk 
sampai lewat, melebihi 6 jam untuk sampai ke hospital manakala pesakit strok jenis 
pendarahan berkemungkinan untuk sampai lebih awal, diantara 3 sehingga 6 jam. 
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ABSTRACT 
REVIEW OF CLINICAL PREDICTORS OF 
HAEMORRHAGIC AND ISCHAEMIC STROKE IN 
EMERGENCY DEPARTMENT, BKL: 
AN OBSERVATIONAL STUDY 
INTRODUCTION: 
The emergence of reperfusion therapy in acute ischemic stroke has revolutionized 
the management of an acute ischemic stroke. However, this approach have been 
hampered by lack of urgency from the patients itself, public and medical personnels. 
These were probably due to lack of knowledge in current management from all involved. 
Aim of this study is to review common signs and symptoms in stroke and to see if 
we can safely differentiate between types of stroke. This study also wants to look at time 
taken by each patient to arrive at Emergency Department. 
xvi 
METHOD: 
A cross-sectional observational study for all clinically diagnosed stroke patients 
admitted to Hospital Kuala Lumpur from January to May 2005 after fulfilling the 
inclusion and exclusion criteria. All patients were subjected to brain Computed 
Tomography. 
Common signs and symptoms on admission that were reviewed are: Age, sex, 
ethnic, Glasgow Coma Scale, Systolic and Diastolic blood pressure, loss of 
consciousness, headache and vomiting. 
RESULTS: 
A total of one hundred and forty-three (Eighty-eight male and fifty-five female) 
patients were included in this study. Sixty-four point three percent of patients presented 
to Emergency Department six hours after the initial symptoms started with majority of 
them are ischemic stroke patients. Haemorrhagic stroke patients are more likely to be 
younger (mean age of fifty-one years versus fifty-six years), to have symptoms of loss of 
consciousness (twenty-three point one percent: p value less than 0.001), headache 
(Eighteen point two percent: p value less than 0.001) and vomiting (nine point eight: p 
xvii 
value less than 0.001), and lower Glasgow Coma Scale (mean=9, Standard 
Deviation=2.8) and higher Systolic blood pressure (mean=174.77, Standard 
Deviation=22.5). 
CONCLUSION: 
Significant predictors for stroke patients to have higher probability of 
haemorrhagic type are lower age group, presented with loss of consciousness, headache 
and vomiting, and have lower Glasgow Coma Scale and higher Systolic blood pressure. 
Ischemic stroke patients are more likely to present late, more than six hours to 
Emergency Department while Haemorrbagic stroke patients are more likely to present 
earlier, within three to six hours. 
xviii 
CHAPTER 1 
INTRODUCTION 
Stroke is ranked among the top 3 leading causes of death in most countries and the 
leading cause of brain injury and disability in adults (Guidelines 2000 for Cardiopulmonary 
Resuscitation and Emergency Cardiovascular Care). Stroke inflicts a devastating physical, 
emotional and financial toll in its victim, their families and healthcare systems all over the 
world. In 1998 alone, the U.S population endured more than 600,000 strokes resulting 
158,448 deaths and the loss of functional independence for countless others (AHA, 2000). 
With an estimated 750,000 new strokes and more than million hospitalizations 
occurring in U.S each year, the importance of stroke as major cause of morbidity and 
mortality cannot be overemphasized. Approximately 8% of those suffering an acute stroke 
die within 30 days and 290/o of stroke patients are dead at 1 year. Of those who survive, 
16% of stroke patients require institutional care, another 31% require assistance caring for 
themselves and 20% of stroke survivors need walking assistance (Jauch et al., 2001). Up to 
one third of stroke survivors suffer from major depression and depression is common in 
care providers also. The direct and indirect economic impact of acute stroke in America are 
no less severe, with an estimated cost ofUSD 43 billion per year. 
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Until recently, care of stroke patient was largely supportive, focusing on prevention 
and treatment of respiratory and cardiovascular complications with little hope of affecting a 
positive outcome. No specific therapy was available to alter the course and extent of the 
evolving stroke. Therefore, little emphasis was placed on rapid transport or intervention. 
The last decade, however, has seen the emergence of a new treatment for acute stroke, 
energizing stroke care providers and spreading a sense of optimism among those who seek 
to alter the course of this terrible disease. 
Since 1996, the US FDA has approved the use of intravenous rtP A in acute 
ischaemic stroke. This approval was based on the publication of 1995 results of NIH 
National Institute of Neurological Disorders and Stroke (NINDS) trial evaluating the use of 
intravenous rtP A. This trial demonstrated, for the first time, that stroke was a treatable 
disease in carefully selected patients who received rtP A within 3 hours of symptoms with at 
least 30% more likely to have minimal or no disability at 3 months compared to those 
treated with placebo. Fibrinolytic therapy now offers health care providers an opportunity 
to possibly limit the extent of neurological damage and to improve the outcome in 
ischaemic stroke patients. These have revolutionized the approach and urgency in 
management of acute stroke. The availability of neurosurgical expertise in almost all 
general hospitals in Malaysia also helps to minimize the extent of damage in haemorrhagic 
stroke. 
Computed tomography have been used to confirm and differentiate the diagnosis of 
either haemorrhagic and ischaemic stroke (Osborn & Winthrop, 1994). CT is extremely 
valuable and this was recognized early on in the clinical application of diagnostic CT. In 
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1973, Ambrose stated "in the overall investigation of cerebrovascular disease, 
computerized transverse axial scanning will, without a doubt, come to be invaluable means 
of distinguishing between haemorrhage and infarction" (Ambrose, 1973). 
CT is the study of choice for acute head injuries and for detecting spontaneous 
subarachnoid haemorrhage. CT is indicated once an emergency physician suspects that a 
structural lesion is causing the headache. CT should be done promptly on any patient if 
thrombolysis is applicable (Sarkarati & Reisdorff, 2002). 
In the recent years, few other modalities have emerged that are more sensitive in 
detecting early stroke such as Positron Emission Tomography (PET) and Magnetic 
Resonance Imaging (MRI). However, due to its high cost, time-consuming and may 
hamper continuous observation of acutely ill patients made it unpractical as first line 
investigation in diagnosing stroke. The last few years, the role of CT scan have been 
elevated due to recent update of management on both types of stroke. Both need different 
approach in managing the patient and have different prognosis. Effective treatment of one 
stroke type may be disastrous when applied to another stroke type. 
However, despite this advancement of approach in management of stroke, we are 
still lacking in all steps of "stroke chain of survival". This chain of survival highlights the 
seven step of management of stroke or '7D's: Detection, Dispatch, Delivery, Door, Data, 
Decision and Drug (AHA, 1997). The first three 'D' represent the responsibility and 
awareness of Basic Life Support (BLS) providers in the community in recognising the 
stroke symptoms and to activate the emergency medical services. The latter four 'D' 
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represents the hospital responsibility in managing patient that came with symptoms of acute 
stroke. These approaches are similar to patient that presents with acute myocardial 
infarction, which is essentially early recognition of stroke and rapid triage, evaluation in 
Emergency Deparbnent and definitive management. (Table 1.1) 
TABLE 1.1 STROKE CHAIN OF SURVIVAL OR SEVEN 'D's 
(Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care). 
Detection Awareness of stroke signs and symptoms by the 
patient or bystanders 
Dispatch Activation of EMS systems, priority dispatch and 
rapid EMS response 
Delivery Rapid transport to the appropriate facility, en-route 
assessment and prehospital notification 
Door Emergency department triage 
Data Emergency department evaluation 
Decision Selection of appropriate therapy and intervention 
Drug Delivery of therapeutics 
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Performing an extensive neurological examination outside the hospital is 
impractical. As such, stroke screen or scale has been used with much success in the U.S. 
These stroke scales have been validated and most cities have its own. Two of most 
common and extensively used are Cincinnati Prehospital Stroke Scale (Table 1.2) (Kothari 
et al.,1999) and Los Angeles Prehospital Stroke Screen (LAPSS) (Table 1.3) (Kidwell et 
al.,2000). The Cincinnati Scale is used to elicit any of the 3 major physical findings 
suggestive of stroke: Facial droop, arm drift and abnormal speech (Kothari et al., 1999). 
LAPSS requires the examiner to rule out other cause of altered level of consciousness and 
then identify asymmetry in facial smile/grimace, grip or arm strength. Asymmetry in any 
category indicates a possible stroke (Kidwell et al., 1998, Kidwell et al., 2000). These two 
scales are sensitive and specific in identifying stroke patients (Kidwell et al., 1998, Kothari 
et al., 1999, Kidwell et al., 2000). Either evaluation can be performed quickly. 
TABLE 1.2 CINCINNATI PREHOSPITAL STROKE SCALE 
Normal Abnormal 
Faeial droop Both sides of face move One side of face does not 
(Have patient show teeth or equally well move as well as the other 
smile) side 
Arm drift Both arms move the same or One arm does not move or 
(Have patient close eyes and both arms do not move at all one arm drifts down 
hold both arms straight out 
for 10 seconds) 
Abnormal speeeh Correct words with no Patient slurs words, use the 
slurring wrong words or is unable to 
speak 
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TABLE 1.3 LOS ANGELES PREHOSPITAL STROKE SCREEN (LAPSS) 
For evaluation of acute, non comatose, non traumatic neurological complaint: if items 1 
through 6 are ALL checked "YES" (or unknown), notify the receiving hospital before 
arrival of the potential stroke patient. If any are checked ''NO", follow appropriate 
treatment protocol 
Interpretation: 93% of patients with stroke will have positive findings (all item checked 
"YES" or "unknown") on the LAPSS (sensitivity=93%) and 97% of those with positive 
findings will have a stroke ( specificity=97% ). The patient may still be having a stroke if 
LAPSS criteria are not met. 
CRITERIA YES UNKNOWN NO 
1. Age > 45 years 
2. History of seizures or epilepsy 
absent 
3. Symptom duration < 24 hours 
4. At baseline, patient is not 
wheelchair bound or bedridden 
5. Blood glucose between 60 -
400 
6. Obvious asymmetry in any of 
the following 3 categories (must Egual RWeak LWeak 
be unilateral) 
• Facial smile/grimace 
• Grip 
• Ann strength 
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TABLE 1.4 NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND 
STROKES (NINDS) RECOMMENDED STROKE EVALUATION TARGETS 
FOR POTENTIAL THROMBOLYTIC CANDIDATES 
(Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care). 
Time interval Time target 
Door to doctor 10 minutes 
Access to neurological expertise 15 minutes 
Door to CT completion 25 minutes 
Door to CT interpretation 45 minutes 
Door to treatment 60 minutes 
Admission to monitored bed 3 hours 
• • Target times will not be achieved in all cases, but they represent a reasonable goal 
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CHAPTER2 
OBJECTIVES 
2.1 AIM: 
1. To evaluate time taken for each stroke patient from the initial symptoms to 
assessment by doctors. 
2. To review the presenting symptoms that is commonly associated with 
haemorrhagic stroke. 
3. To review the presenting signs that is commonly associated with haemorrhagic 
stroke. 
4. To review the presenting symptoms that is commonly associated with ischemic 
stroke. 
5. To review the presenting signs that is commonly associated with ischemic stroke. 
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2.2 SELECTION OF PATIENTS 
All patients with haemorrhagic and ischaemic stroke (confirmed by CT scan 
brain) that are admitted to HKL during the study period. 
2.2.1 Inclusion criteria 
• Clinical diagnosis of stroke 
• Non trauma case 
• Age> 18 years 
2.2.2 ExchJsio r, c riteria 
• Referred case 
• Trauma case 
• Age < 18 years 
• Recurrence of stroke 
• History of serious head trauma 
• Alcohol intoxication 
• History of brain pathology (other than vascular in origin) 
• Blood glucose level < 3.5 mmol/L 
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2.3 RESEARCH HYPOTHESIS 
1. Majority of patients presented more than 6 hours after initial symptoms 
ii. Patient that presented to Emergency Department, HKL with stroke cannot be 
safely differentiate types of stroke based on clinical presentation alone 
2.4 DEFINITION 
Stroke 
• Rapidly developed clinical signs of focal disturbance of cerebral function, lasting 
more than 24 hours or leading to death, with no apparent cause other than 
vascular origin. (WHO) 
• Results from any disease process that disrupts vascular blood flow to a distinct 
region of brain (Tintinalli et al., 2000) 
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CHAPTER3 
LITERATURE REVIEW 
3.0 BACKGROUND 
Effective treatment of the patient who has sustained an acute ischaemic stroke 
requires rapid assessment and early intervention. The window of time for therapy, as 
determined on the basis of animal and human studies, is limited to the first few hours 
after the onset of stroke. Currently, only thrombolysis with recombinant tissue 
plasminogen activator (rtPA) within 3 hours of stroke onset has been shown to be 
beneficial (NINDS, 1995). 
The early treatment of stroke is complicated by several potential systemic delays. 
Patients and families may be unaware of the clinical manifestations of stroke and as a 
result may not seek emergency care. Emergency medical personnel may triage stroke 
victims to a low priority, resulting in delay in transport and evaluation. Imaging with 
computed tomography (en may not be immediately available. Therapeutic nihilism with 
regard to stroke in the general medical community may preclude rapid triage and 
treatment. Emergency and primary care physicians may rely on consultation with 
neurologists to treat patients with focal deficits. Neurologists tend to concentrate on a 
careful history and treatment to localize and classify a neurologic lesion but typically are 
not trained in rapid diagnosis and treatment (Kasner & Grotta, 1997). Similar roadblocks 
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were perceived when thrombolysis was a new treatment for acute myocardial infarction 
(MI) (Sharkev et al., 1989; Gonzalez et al., 1992). 
However, most centres now adhere to the minimum time-to-treatment 
recommendations established by the American Heart Association Emergency Cardiac 
Care Committee and the National Heart Attack Alert Programme Coordinating 
Committee, and eligible acute MI patients are given thrombolytic agents within 30 - 60 
minutes of arrival. The Brain Attack Coalition, supported by the American College of 
Emergency Physicians, the American Academy of Neurology and the National Stroke 
Association, seeks to improve both public and medical education regarding the 
importance of time. 
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3.1 PATHOPHYSIOLOGY 
Pathophysiology of ischaemic stroke was the basis of management of acute 
stroke, which was a complex but consistent series of events that occurs after abrupt 
interruption of cerebral blood flow. It is a dynamic process that depends on both the 
severity of ischaemia and its duration. The ischaemic cascade starts within seconds to 
minutes of loss of perfusion, such that obstruction of blood vessels creates a central area 
of irreversible infarction and a surrounding area of potentially reversible "ischaemic 
penumbra". (Hossman, 1994; Fisher & Garcia, 1996). The penumbral region is 
fundamentally salvageable and is therefore the ultimate target of therapy. 
At the cellular level, protein synthesis initially ceases as the ischaemic neuron 
attempts to conserve its rapidly waning energy stores. Membrane ion-transport systems 
fail and the neuron becomes depolarized. Membrane depolarization results in calcium 
influx, which in turn causes release of stores neurotransmitters. Glutamate, the major 
excitatory neurotransmitter in the brain, is released in large quantities. It worsens the 
cellular insult by further increasing intracellular calcium and by depolarizing other 
metabolically compromised neurons. Other neurotransmitters may also intensify the 
injury. The massive calcium influx stimulates several enzymes, which becomes 
unregulated and may cause destruction of cellular homeostatic mechanisms, cytoskeleton, 
mitochondria and cell membrane. Free radical formation and nitric oxide synthesis may 
further contribute to neuronal damage. 
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During the hours to days after a stroke, the ischaemic territory activate specific 
genes. Formation of cytokines and cell adhesion molecules stimulates local inflammation 
and may further impair blood flow in the microcirculation. Finally, apoptotic gene 
activation may promote programmed cell death in the population of surviving neurons. 
Without timely intervention, the entire ischaemic penumbra eventually succumbs to these 
progressive insults and becomes confluent with the infarct core. 
In human beings, the presence of an ischaemic penumbra may be detected 
through the use of positron emission tomography (PET) (Heiss & Herholz, 1994; 
Marchal et al., 1996) and the magnetic resonance techniques of diffusion- and perfusion-
weighted imaging. (Rother et al., 1996; Warach et al., 1996; Fisher et al., 1995). Detailed 
descriptions of these methods are beyond the scope of this review, but they provide 
evidence for the existence of an ischaemic penumbra surrounding an infarct core in 
patients who have sustained acute strokes. Furthermore, these techniques demonstrate 
that in most cases the penumbra merges with the infarct core within several hours of the 
onset of stroke. (Heiss & Herholz, 1994; Marchal et al., 1996) 
On this basis of current understanding of ischaemic cascade and the evolving 
penumbra, it appears that acute intervention must occur very early for a substantial 
portion of brain tissue to be preserved. Subsequently, several animal studies were done 
which suggested reperfusion must occur within 3 hours. (Marchal et al., 1996; 
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Minematsu et al., 1992). Preliminary results from human imaging studies also suggest 
similar time frame. 
As such, the only proven effective therapy for acute stroke also mandates a 3-hour 
window for perfusion. The time window in which to alter the course of the ischaemic 
cascade remains less well defined, but it is also presumed to be relatively brief. 
(Aronowski et al., 1996). However, the cascade comprises many points at which 
intervention may be attempted. 
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3.2 MAJOR ACUTE STROKE TRIALS 
The two major strategies for the treatment of acute stroke are restoration of 
cerebral perfusion and newunal protection. However, only trials of reperfusion by means 
of thrombolysis have demonstrated a positive benefit. 
Restoration of cerebral blood flow after an acute vascular occlusion may be 
achieved by the administration of thrombolytic agents. rtP A and streptokinase are of 
proven efficacy in ~ute MI and are the most extensively studied agents for thrombolysis 
in stroke. However, as demonstrated by the results of several major trials, only rtP A has a 
favourable risk-to-benefit profile in the treatment of stroke. 
The specific choice of thrombolytic drug for the treatment of acute stroke depends 
on several pbarmacokinetic factors. Although both rtP A and streptokinase convert 
plasminogen to plasmin, which in tum causes cleavage of fibrin and ultimately results in 
lysis of a clot, the two agents have different mechanisms of action. rtP A specifically 
activates plasminogen that is already bound to a thrombus, whereas streptokinase 
activates unbound circulating plasminogen, causing systemic depletion of fibrinogen. The 
effects of streptokinase are therefore much longer-acting and less clot-specific than those 
of rtP A but rtPA effects significantly more rapid lysis than streptokinase in coronary 
trials (Anderson & Wilierson, 1993). In the treatment of acute MI, streptokinase does not 
necessarily require the concurrent use of heparin because of its induction of a prolonged 
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lytic state, but rtP A has a relatively brief effect in the absence of concurrent heparin 
(Anderson & Wilierson, 1993). Streptokinase is substantially less expensive than rtP A. 
The timing of thrombolysis is of paramount importance. As described earlier, 
ischaemic brain tissue may be salvageable if reperfusion occurs before the tissue is 
irreversibly damaged. Moreover, the risk of haemorrhage appears to increase once the 
ischaemic tissue becomes oedematous (Hacke et al., 1997; von Kummer et al., 1997). On 
the basis of findings from animal studies and preliminary human studies, the National 
Institute of Neurological Disorders and Stroke (NINDS) rtP A study used a 3-hour limit 
for initiation of therapy. In the other trials of rtP A and streptokinase, patients were given 
the agents between 3 and 6 hours after the onset of stroke. 
The European Cooperative Acute Stroke Study (ECASS) 1995 was a randomized, 
prospective, multicentre, double-blind, placebo-controlled study of 620 patients who had 
sustained acute ischaemic hemispheric stroke. Patient were randomized to receive 
treatment with intravenous rtP A 1.1 mglkg or placebo within 6 hours of the onset of 
stroke. The median time from stroke onset to treatment was 4.3 hours. The primary 
endpoints were the Barthel Index (a 1 00-point scale of independence with regard to 
activities of daily living) and the Modified Rankin Scale (a 5-point scale of disability) at 
90 days. No significant benefit of rtP A over placebo was noted in the overall intention-to-
treat analysis with regard to the primary endpoints. However, 109 patients (17.4%) 
included in this analysis were considered protocols violations and should have been 
barred from enrolment because they fulfilled at least one exclusion criterion. In the 
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remaining patients referred to as the target population, a significant improvement in 
Rankin Scalescore was evident at 90 days. Furthermore, several secondary endpoints--
including the combined Barthel and Rankin scores, speed of neurologic recovery and the 
length of hospital stay-were significantly improved by rtP A in both the intention-to-
treat and target-population analyses. Although rtPA-treated patients had a higher 
incidence of parenchymal intracerebral haemorrhage (19.8% versus 6.5%; P<0.001), no 
significant difference was found in mortality at 30 days between the rtP A and placebo 
groups (17.9% versus 12.7%; not significant) in either analysis (Kasner SE & Grotta, 
1997). 
Most protocols violations were the result of enrolment of patients with CT 
exclusion criteria: major signs of early infarction, primary haemorrhage, or 
unreadable/unavailable CT scan. Patients in the protocol-violation group who were 
treated with rtP A had a much higher risk of haemorrhage and death than those given 
placebo. On the basis of the differences between intention-to-treat and the target-
population analyses, the authors concluded that treatment of an unselected stroke patient 
population within 6 hours of stroke onset is not recommended. 
The NINDS rtP A stroke study was a randomized, prospective, multicentre, 
double-blind, placebo-controlled study of 624 patients who had sustained acute iscbaemic 
stroke. Patients who fulfilled the inclusion and exclusion criteria (refer Table 3.1) were 
randomly assigned to receive intravenous rtPA 0.9 mglkg or placebo within 3 hours of 
the onset of symptoms. Half of the patients were treated within 90 minutes. The study 
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was divided into 2 parts, each with a specific primary endpoint. In part 1, the effect of 
rtP A within 24 hours of stroke, was measured on the basis of complete resolution of 
deficit or improvement of at least 4 points on the National Institute of Health Stroke 
Scale (NIHSS, a 42-point scale of specific neurologic deficits); 3-month outcome was a 
secondary endpoint. On the basis of the analysis of part 1, part 2 was designed to assess 
the benefit of rtP A at 3months as determined by a global statistic comprising the Barthel 
Index, Modified Rankin ·Scale, Glasgow Outcome Scale and the NIHSS. Investigators 
remained blinded to the results of part 1 until both parts were completed. Part 1 failed to 
demonstrate a significant effect of rtP A on the primary endpoint at 24hours, although 
rtP A was associated with significant improvement in the median NIHSS at 24 hours in 
the secondary analysis and 3-month outcome was also improved. Part 2 demonstrated 
significant improvement in clinical outcome at 3 months in patients treated with rtP A in 
the global statistic and in each of its 4 individual components. 
Overall, the odds ratio for a favourable outcome in the rtP A group was 1. 7 (95% 
confidence interval, 1.2 to 2.8; P=0.008). This result was achieved with a relatively 
smaller study size than the trials of thrombolysis for MI, and was both statistically 
significant and clinically robust. The absolute increase in the number of patients with 
minimal or no deficit in part 2 was 11% (relative benefit, 55%) by the NIHSS and 13% 
(relative benefit, 50%) by the Rankin Scale. The benefit ofrtPA was realized regardless 
of the presumed cause of stroke: large-vessel occlusive disease, small-vessel occlusive 
disease and cardioembolism. The rate of symptomatic intracerebral haemorrhage in the 
first 36 hours was significantly greater in the patients treated with rtP A than in those 
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given placebo (6.4% versus 6%; P<O.OOl), but there was no significant difference in 
mortality at 3 months (17% versus 21%; not significant). 
The division of the NINDS rtP A trial into two parts has created some confusion in 
the medical community. Each part was essentially independent of the other and each had 
a unique hypothesis but the methods were identical and the data were published together. 
Many expected that if thrombolysis was beneficial, it should have had an early rather 
than a late effect at 3 months. This assumption might yield the conclusion that the 
negative results of part 1 should therefore cast the findings of the overall analysis into 
doubt. Such a conclusion is unwarranted. The specific hypothesis of part 1-that rtP A 
would cause a 4-point improvement on the NlliSS or complete resolution of symptoms 
within 24 hours-was not supported by the statistics. There was no significant difference 
in the proportion of patients with early improvement or excellent outcome in the rtP A 
(47%) and placebo groups (39%). However, when median NIHSS scores were evaluated, 
there was 4-point difference in favour of the rtP A treated group (NIHSS, 12; placebo,8; 
P< 0,02). A similar benefit was observed in the 24-hour outcome of the patients in part2 
of the study (Kasner SE & Grotta, 1997). 
Because of the methodologic differences between the NINDS and ECASS 
studies, direct comparisons are limited. The major difference was the acute time frame. 
The use of rtP A is therefore only recommended when therapy can be initiated within 3 
hours. However, as intimated by the ECASS analysis of the target population, careful 
selection of patients with appropriate CT criteria may eventually allow for treatment 
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beyond 3 hours. Although the CT criteria for the NINDS trial only excluded patients with 
haemorrhage, a retrospective analysis of the ECASS data suggests that major early infarct 
signs should be considered a contraindication to the rtP A treatment in any time frame 
(Hacke et al.,l997; von Kummer et al., 1997). These early CT changes may indicate that 
the time of onset is earlier than reported or that the injured brain tissue is already beyond 
the point of recovery. The sequelae of subtle CT changes are less clear, and they should 
not be considered a contraindication to therapy in the 3 hours immediately after the stroke 
Kasner SE & Grotta, 1997). The European study also used a higher dose of rtP A than did 
the NINDS study. 
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INCLUSION 
CRITERIA 
EXCLUSION 
CRITERIA 
Historical 
1. Age> 18 years 
2. Clinical diagnosis of ischaemic stroke, with 
onset of symptoms within 3 hours of initiation 
of treatment 
3. CT (non-contrast) without evidence of 
haemorrhage 
1. Stroke or head trauma in previous 3 months 
2. History of intracranial haemorrhage 
3. Major surgery or other serious trauma in previous 14 
days 
4. Gastrointestinal or genitourinary bleeding in previous 
21 days 
5. Lumbar puncture in previous 7 days 
6. Pregnant or lactating female 
Clinical 
1. Rapidly improving stroke symptoms 
2. Seizure at onset of stroke 
3. Symptoms suggestive of subarachnoid haemorrhage 
even if CT is normal 
4. Persistent systolic BP > 185 or diastolic BP >110 mm 
Hg or requiring aggressive therapy to control BP 
5. Clinical presentation consistent with acute Ml or post-
MI pericarditis, requires cardiologic evaluation prior to 
treatment 
Radiographic 
1. CT evidence of haemorrhage 
2. CT with evidence of hypodensity and/or effacement 
of cerebral sulci in more than one third of middle 
cerebral artery territory 
Laboratory 
1. Glucose < 50 or> 400 mgldl 
2. Platelets< 100,000/mm3 
3. On warfarin, and prothrombin time (PT) > 15 seconds 
4. On Heparin therapy within 48 hours, and partial 
thromboplastin time (PTT) is elevated 
TABLE 3.1 Inclusion and exclusion criteria for thrombolysis of acute ischaemic 
stroke (Multicentre Acute Stroke Trial- Italy (MAST -1), 1995) 
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Three major trials in Streptokinase have demonstrated that it is neither beneficial 
nor a safe treatment for acute ischaemic stroke when coronary doses are given up to 6 
hours after stroke onset. All three trials were randomized, prospective, multicentre studies 
and all three were terminated before completion because of unacceptable mortality rates. 
In the Multicentre Acute Stroke Trial- Italy (MAST-I), 622 patients with acute 
ischaemic stroke were randomized within 6 hours of stroke onset. Patients received 
intravenous 1.5 megaunits Streptokinase or Aspirin 300 mg daily for 10 days, both or 
neither. Neither streptokinase, nor aspirin, nor the combination significantly improved 
outcome. Streptokinase was also associated with significant increase in the 1 0-day 
mortality rate compared with controls (27% versus 12%; P<O.OOOOl), although the 
incidence of haemorrhage with streptokinase alone (6%) was similar to that found with 
rtPA in the NINDS study. 
The Multicentre Acute Stroke Trial - Europe (MAST -E) enrolled 310 patients 
within 6 hours of the onset of symptoms. Patients received either intravenous 
streptokinase 1.5 megaunits or placebo. Approximately two thirds of patients also 
received concomitant treatment with heparin, many within the first 12 hours after the 
administration of streptokinase or placebo. There was a non significant trend toward less 
disability, as measured with the Rankin Scale, in patients who received streptokinase. 
However, mortality was greater in those treated with streptokinase than in those given 
placebo, both at 10 days (34% versus 18.2%; P=0.002) and 6 months ( 46.8% versus 
38.3%; P=13; not significant) 
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The Australian Streptokinase (ASK) trial recruited 340 patients within 4 hours of 
onset of acute stroke. Patients were randomized to receive placebo or treatment with 
intravenous streptokinase 1.5 megaunits. Aspirin was also administered whenever 
possible. Overall, streptokinase afforded no benefit with regard to outcome on the Barthel 
Index at 3 months and it was associated with significantly increased risk of intracerebral 
haemorrhage (13.2% versus 3% with placebo; P<O.Ol). Mortality at 3 months was also 
significantly greater with streptokinase (36.2% versus 20.5%; P<O.OS). However, these 
poor outcomes were predominantly attributable to treatment after 3 hours. Among the 70 
patients treated during the 3-hour window, the authors noted a non significant trend 
toward improved outcome without excess mortality. 
Thrombolysis is an effective therapy for acute stroke, but only one thrombolytic 
agent, rtP A, has proven efficacy and safety. Early and rapid assessment is essential 
because treatment must begin in the 3 hours after onset. Patients must be selected on the 
basis of rigid adherence to the inclusion and exclusion criteria to limit the risk of 
haemorrhagic complications. Careful evaluation of the initial CT scan also appears to be 
important in reducing the risk of intracranial haemorrhage. Finally, the concurrent use of 
anticoagulant and antiplatelet agents must be strictly avoided for the first 24 hours. 
Continuing research is focused on methods to better identify those patients who may 
benefit most from thrombolysis with rtP A, as well as on improved means to exclude 
those at highest risk for haemorrhagic complications (Kasner & Grotta, 1997). 
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